MAGL Inhibition in Prevention and Treatment of Alzheimer's Disease

MAGL 抑制预防和治疗阿尔茨海默病

• 批准号: 8246406
• 负责人: CHU CHEN
• 金额: $ 18.11万
• 依托单位: LSU HEALTH SCIENCES CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8246406
• 关键词: 2-arachidonylglycerol; Abeta clearance; Abeta synthesis; Agonist; Alzheimer disease prevention; Alzheimer' s Disease; Amyloid beta-Protein; Animal Model; Animals; Anti-Inflammatory Agents; Anti-inflammatory; Apoptotic; Brain; CNR1 gene; CNR2 gene; Cells; Cessation of life; Chronic; Cleaved cell; Clinical; Cognitive deficits; Deposition; Deterioration; Development; Disease Progression; Endocannabinoids; Enzymes; Gene Expression; Goals; Health; Hippocampus (Brain); Hydrolysis; Impaired cognition; In Situ Nick-End Labeling; Laboratories; Learning; Lipids; Long-Term Potentiation; Mediator of activation protein; Memory; Memory impairment; Mental disorders; Monoacylglycerol Lipases; Nerve Degeneration; Neurodegenerative Disorders; Neurons; PPAR gamma; PTGS2 gene; Pathogenesis; Pathologic Processes; Pharmaceutical Preparations; Physiological; Plant Roots; Play; Prevention; Production; Property; Research; Role; Signal Pathway; Signal Transduction; Symptoms; Synapses; Synaptic Transmission; Synaptic plasticity; System; TNF gene; Testing; Therapeutic Intervention; Transgenic Animals; Transgenic Mice; United States Food and Drug Administration; abeta accumulation; abeta deposition; beta-site APP cleaving enzyme 1; cannabinoid receptor; caspase-3; cognitive function; fluoro jade; inhibitor/antagonist; lipid mediator; memory retention; nervous system disorder; neuroinflammation; neuropathology; novel; prevent; synaptic function

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive deterioration of cognitive function and loss of memory in association with widespread neuronal death. Currently, however, there are no effective medications to cure or treat AD. Endocannabinoids (eCBs) are endogenous lipid signaling mediators involved in a variety of physiological, pharmacological, and pathological processes and capable of modulating synaptic transmission and plasticity by activation of the cannabinoid receptor (CB1R), a predominantly expressed type of cannabinoid receptors in the brain. Growing evidence suggests that 2- arachidonoylglycerol (2-AG), the most abundant eCB and a full agonist for CB1 and CB2 receptors, renders anti-inflammatory and neuroprotective properties. Neuroinflammation is at the root of many chronic neurological and mental disorders and is believed to contribute to the pathogenesis of neurodegenerative diseases such as AD. However, little is known about whether 2-AG plays an important role in production of beta-amyloid, the hallmark of AD, and beta-amyloid-induced synaptic and memory deficits. The goal of the proposed project is to understand the role of 2-AG in development and neuropathology of AD. In this exploratory study application, we will test our hypothesis that inhibition of monoacylglycerol lipase (MAGL), an enzyme that hydrolyzes 2-AG, is able to prevent and reduce synthesis of Abeta and alleviate neuropathology in an animal model of AD. This hypothesis will be tested by accomplishing three specific aims: Aim 1: To test the hypothesis that elevation of endogenous 2-AG is capable of reducing or slowing production and deposition of beta-amyloid in the brain of APP transgenic mice; Aim 2: To test the hypothesis that inhibition of MAGL is able to inhibit neuroinflammation and prevent neurodegeneration in APP transgenic animals; Aim 3: To test the hypothesis that inhibition of MAGL is able to prevent or rescue deficits in long-term synaptic plasticity and cognitive function in APP transgenic mice. The proposed application will tackle a novel and intriguing topic that endogenous 2-AG is crucial in neuropathology of AD. The results generated from this application will not only provide experimental evidence that inhibition of MAGL is capable of slowing or decreasing synthesis and accumulation of beta-amyloid, ameliorating beta-amyloid-induced synaptic and memory deficits, and preventing neurodegeneration, but also indicate that approaches that elevate endogenous 2-AG by inhibiting its hydrolysis or facilitating its synthesis are new efficacious therapeutic interventions for preventing, alleviating or treating Alzheimer's disease.

描述（由申请人提供）：阿尔茨海默病（AD）是一种神经退行性疾病，其特征在于认知功能的进行性恶化和与广泛神经元死亡相关的记忆丧失。然而，目前还没有有效的药物来治愈或治疗AD。内源性大麻素（eCB）是参与多种生理、药理和病理过程的内源性脂质信号传导介质，并且能够通过激活大麻素受体（CB 1 R）来调节突触传递和可塑性，大麻素受体是大脑中主要表达的大麻素受体类型。越来越多的证据表明，2-花生四烯酰甘油（2-AG），最丰富的eCB和CB 1和CB 2受体的完全激动剂，提供抗炎和神经保护特性。神经炎症是许多慢性神经和精神障碍的根源，并且被认为有助于神经退行性疾病如AD的发病机制。然而，很少有人知道2-AG是否在β-淀粉样蛋白的产生中起重要作用，β-淀粉样蛋白是AD的标志，β-淀粉样蛋白诱导的突触和记忆缺陷。该项目的目标是了解2-AG在AD的发展和神经病理学中的作用。在本探索性研究申请中，我们将检验我们的假设，即在AD动物模型中，抑制单酰基甘油脂肪酶（MAGL）（一种水解2-AG的酶）能够预防和减少Abeta的合成并减轻神经病理学。该假设将通过实现三个具体目的来检验：目的1：检验内源性2-AG升高能够减少或减缓APP转基因小鼠脑中β-淀粉样蛋白的产生和沉积的假设;目的2：检验抑制MAGL能够抑制APP转基因动物中的神经炎症和预防神经变性的假设;目的3：验证抑制MAGL能够预防或挽救APP转基因小鼠长期突触可塑性和认知功能缺陷的假设。所提出的应用将解决一个新的和有趣的话题，即内源性2-AG在AD的神经病理学中至关重要。本申请产生的结果不仅提供了MAGL抑制能够减缓或减少β-淀粉样蛋白的合成和积累、改善β-淀粉样蛋白诱导的突触和记忆缺陷以及预防神经变性的实验证据，而且还表明通过抑制内源性2-AG水解或促进其合成来提高内源性2-AG的方法是用于预防、缓解或治疗阿尔茨海默病。